AR014784A1 - A NUCLEIC ACID CODIFYING A POLYPEPTIDE THAT PRODUCES AN IMMUNE PROTECTIVE RESPONSE AGAINST AN ALFA-VIRUS, A VACCINE UNDERSTANDING IT, ITS USE IN THE PREPARATION OF MEDICINES, A MUTANT OF SUCH ALFAVIRUS, A VACCINE VIRUS AND A PLASIN - Google Patents
A NUCLEIC ACID CODIFYING A POLYPEPTIDE THAT PRODUCES AN IMMUNE PROTECTIVE RESPONSE AGAINST AN ALFA-VIRUS, A VACCINE UNDERSTANDING IT, ITS USE IN THE PREPARATION OF MEDICINES, A MUTANT OF SUCH ALFAVIRUS, A VACCINE VIRUS AND A PLASINInfo
- Publication number
- AR014784A1 AR014784A1 ARP990101360A AR014784A1 AR 014784 A1 AR014784 A1 AR 014784A1 AR P990101360 A ARP990101360 A AR P990101360A AR 014784 A1 AR014784 A1 AR 014784A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- vaccine
- nucleic acid
- polypeptide
- produces
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title abstract 3
- 230000001681 protective effect Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000013598 vector Substances 0.000 abstract 3
- 241000710929 Alphavirus Species 0.000 abstract 2
- 241000701161 unidentified adenovirus Species 0.000 abstract 2
- 208000000832 Equine Encephalomyelitis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940124551 recombinant vaccine Drugs 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un ácido nucleico que codifica un polipéptido que produce una respuesta inmune protectora contra un alfa-virus como ser un Virus de Encefalitis Equinade Venezuela, en un mamífero al cual se administra el mismo, careciendo dicho ácido nucleico deuna senal de targeting nuclear competente en el gen de cápsida.Los ácidos nucleicos son expresados a niveles aumentados en vectores como ser vectores de adenovirus. En particular, se describe un mutante de delecion de unalfavirus. Los vectores tales como los adenovirus recombinantes o virus de vacuna recombinante y plásmidos, también se describen como vacunas quecontienen los mismos. El uso de estos elementos en la preparacion de un medicamento para el uso como una vacuna protectora contra alfa-virus es ademásun aspecto de la invencion.A nucleic acid encoding a polypeptide that produces a protective immune response against an alpha-virus such as an Equine Encephalitis Virus Venezuela, in a mammal to which it is administered, said nucleic acid lacking a nuclear targeting signal competent in the gene capsid. Nucleic acids are expressed at increased levels in vectors such as adenovirus vectors. In particular, an unalfavirus deletion mutant is described. Vectors such as recombinant adenoviruses or recombinant vaccine viruses and plasmids are also described as vaccines containing them. The use of these elements in the preparation of a medicament for use as a protective vaccine against alpha-virus is also an aspect of the invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9806525.3A GB9806525D0 (en) | 1998-03-27 | 1998-03-27 | Recombinant virus |
| GBGB9825053.3A GB9825053D0 (en) | 1998-03-27 | 1998-11-17 | Recombinant virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014784A1 true AR014784A1 (en) | 2001-03-28 |
Family
ID=10829333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101360 AR014784A1 (en) | 1998-03-27 | 1999-03-26 | A NUCLEIC ACID CODIFYING A POLYPEPTIDE THAT PRODUCES AN IMMUNE PROTECTIVE RESPONSE AGAINST AN ALFA-VIRUS, A VACCINE UNDERSTANDING IT, ITS USE IN THE PREPARATION OF MEDICINES, A MUTANT OF SUCH ALFAVIRUS, A VACCINE VIRUS AND A PLASIN |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR014784A1 (en) |
| GB (2) | GB9806525D0 (en) |
-
1998
- 1998-03-27 GB GBGB9806525.3A patent/GB9806525D0/en not_active Ceased
- 1998-11-17 GB GBGB9825053.3A patent/GB9825053D0/en not_active Ceased
-
1999
- 1999-03-26 AR ARP990101360 patent/AR014784A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB9806525D0 (en) | 1998-05-27 |
| GB9825053D0 (en) | 1999-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiang et al. | A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier | |
| KR20210065128A (en) | African Swine Fever Virus Vaccine | |
| ATE471335T1 (en) | VACCINES AGAINST INFECTIONS WITH THE HUMAN CYTOMEGALIVIRUS BASED ON CODONE-OPTIMIZED POLYNUCLEOTIDES | |
| BR9609303B8 (en) | MODIFIED ANKARA VACCINIA VIRUS (MVA), RECOMBINANT, AS A VACCINE CONTAINING THE SAME. | |
| Weger-Lucarelli et al. | A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice | |
| Wang et al. | Protective efficacy of the conserved NP, PB1, and M1 proteins as immunogens in DNA-and vaccinia virus-based universal influenza A virus vaccines in mice | |
| Fleeton et al. | Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine | |
| DE69332831T2 (en) | RECOMBINANT PIGROCK VIRUS | |
| CN105307674A (en) | Improved poxvirus vaccine | |
| CN113226364A (en) | Compositions and methods | |
| WO2013112549A1 (en) | Polynucleotides for treating oncogenic viral polypeptide positive tumors | |
| JP2008522621A (en) | A vaccine to respond quickly to the globally prevalent avian influenza | |
| JP2004501650A5 (en) | ||
| Ramsauer et al. | Chikungunya Virus Vaccines: Viral Vector–Based Approaches | |
| US20240350622A1 (en) | Vaccine Antigen | |
| BR9909173A (en) | nucleic acid, alpha-virus deletion mutant, recombinant adenovirus, vaccine recombinant virus, plasmid, vaccine, and, process to produce an immune protective response to an alpha virus | |
| JP2023528446A (en) | Chimeric adenovirus vector | |
| AR014784A1 (en) | A NUCLEIC ACID CODIFYING A POLYPEPTIDE THAT PRODUCES AN IMMUNE PROTECTIVE RESPONSE AGAINST AN ALFA-VIRUS, A VACCINE UNDERSTANDING IT, ITS USE IN THE PREPARATION OF MEDICINES, A MUTANT OF SUCH ALFAVIRUS, A VACCINE VIRUS AND A PLASIN | |
| EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
| Osorio et al. | Raccoon poxvirus as a mucosal vaccine vector for domestic cats | |
| Elahi et al. | Investigation of the immunological properties of the bovine viral diarrhea virus protein NS3 expressed by an adenovirus vector in mice | |
| Ossevoort et al. | Characterization of an immuno ‘stealth’derivative of the herpes simplex virus thymidine-kinase gene | |
| US12128097B2 (en) | AD35-vectored immunogenic composition for SARS-COV-2 infection | |
| Panicali | Development of live recombinant vaccines using genetically engineered vaccinia viruses. | |
| RU2432963C1 (en) | Method of obtaining peroral vaccine against rabies virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |